IceCure Medical Ltd. 6-K Report: Regulatory Filing for XSense™ Cryoablation System

Here are the key insights extracted from the provided section of the financial report:

1. Document Type: The filing is a Form 6-K, which is typically used by foreign companies to provide information to the SEC.
2. Company Information:

• Name: IceCure Medical Ltd.
• Address: 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504, Israel.

3. Filing Date: The report is dated February 24, 2025, and is identified as Report No. 2 for that month.
4. Securities Exchange Commission (SEC) File Number: 001-40753.
5. Regulatory Submission: The company has submitted a filing for regulatory approval of its next-generation XSense™ Cryoablation System in Israel. This is a significant development indicating potential growth and innovation in their product offerings.
6. Press Release: The press release related to this submission is titled "IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel," and is included as Exhibit 99.1 in the filing.
7. Incorporation by Reference: Specific sections of the press release (first, second, and fourth paragraphs along with the "Forward Looking Statements" section) are incorporated by reference into the Company's Registration Statements on Form F-3 and Form S-8.
8. Signature and Authority: The report is signed by Eyal Shamir, the Chief Executive Officer of IceCure Medical Ltd., which adds credibility and official endorsement to the content of the report.

Summary

IceCure Medical Ltd. is actively pursuing regulatory approval for its new cryoablation system, which could enhance its market position and product line. The inclusion of the press release and the formal nature of the filing reflect the company's commitment to transparency and compliance with SEC regulations.